Furthermore, HER2 amplification can cause acquired resistance to MET inhibitors during crizotinib treatment (221) and resistance in KRASG12C NSCLC, which can be overcome by co-targeting SHP2 (87).Current research indicates that HER2 amplification serves as a prominent mechanism underlying the development of drug resistance in various lung cancer types. Here, MET is linked to non-small cell lung carcinoma.